Skip to main content
. Author manuscript; available in PMC: 2019 Dec 6.
Published in final edited form as: Br J Haematol. 2019 Feb 6;185(6):1021–1042. doi: 10.1111/bjh.15764

Fig 8.

Fig 8.

Non-invasive risk assessment at DLBCL diagnosis by ctDNA. CI, confidence interval; ctDNA, circulating tumour DNA; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival; HR, hazard ratio; IPI, International Prognostic Index; TMTV, total metabolic tumour volume. From Kurtz, D.M. et al Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol, 36, 2845–2853. Reprinted with permission. © 2018 American Society of Clinical Oncology. All rights reserved.